Everand Logo

Welcome to Everand!

  • STAT

    3 China biotech stories to watch in 2019

    In 2018, biotech in China generated relentless news. What's next for 2019?
    by Rebecca Robbins Dec 26, 2018 2 minutes

    As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here. 

    This past year has often felt like the year that China’s biotech sector finally arrived. After years of punching below its weight, in 2018 the industry generated relentless news, milestones, and investment going in both directions across the Pacific.

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
    Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

    Related Books & Audiobooks